Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CXCR1 | P25024 | 11/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 11/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20767328 | 0.87 | RAB9A (0.53) | NPC1ALDH1A1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL21629972 | 0.82 | IDO1 (0.48) | RAB9ASMN1; SMN2CXCR1CXCR2IDO1 | |
| SCHEMBL20766944 | 0.82 | HDAC1 (0.50) | — | |
| SCHEMBL20767333 | 0.81 | RAB9A (0.51) | NPC1ALDH1A1GAARAB9ASMN1; SMN2 | |
| SCHEMBL21630009 | 0.80 | MEN1 (0.48) | NPC1RAB9ASMN1; SMN2CXCR1CXCR2 | |
| SCHEMBL20881365 | 0.77 | IDO1 (0.48) | NPC1ALDH1A1GAARAB9ASMN1; SMN2 | |
| SCHEMBL20766870 | 0.74 | MAPK1 (0.54) | ALDH1A1RAB9ACXCR1CXCR2LMNA | |
| SCHEMBL30566676 | 0.74 | MAPK1 (0.54) | ALDH1A1RAB9ACXCR1CXCR2LMNA | |
| SCHEMBL20766929 | 0.73 | CXCR2 (0.52) | NPC1ALDH1A1GAARAB9ASMN1; SMN2 | |
| SCHEMBL14942693 | 0.72 | AHR (0.56) | NPC1ALDH1A1GAARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112384283-B | Therapeutic heterocyclic compounds | 吉利德科学公司 | 2023-08-15 | — | — | CN | disclosed |
| US-11229638-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11229638-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11186579-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186579-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11040033-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040033-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3817818-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-05-12 | — | — | EP | disclosed |
| CN-112384283-A | Therapeutic heterocyclic compounds | 吉利德科学公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3672970-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | Gilead Sciences, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| CN-111051305-A | Therapeutic heterocyclic compounds | 吉利德科学公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20200031834-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200031834-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019040102-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040102-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229638-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | NPC1 86/4885ALDH1A1 285/4885GAA 99/4885 |
| US-20190192504-A1 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | NPC1 86/4885ALDH1A1 285/4885GAA 99/4885 |
| US-11040033-B2 | Therapeutic heterocyclic compounds | SDHA, CYP11B2, ABCB1 | NPC1 86/4885ALDH1A1 285/4885GAA 99/4885 |
| US-11186579-B2 | Therapeutic heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MAPT, SLC10A1 | NPC1 109/4885ALDH1A1 713/4885GAA 137/4885 |
| US-20200316035-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | SDHA, CYP11B2, ABCB1 | NPC1 86/4885ALDH1A1 285/4885GAA 99/4885 |
| US-20200031834-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MAPT, SLC10A1 | NPC1 109/4885ALDH1A1 713/4885GAA 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.